Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s RWE Data Working Group
Authors:
- Wei Fang DaiWDWei Fang Dai
- Claire de OliveiraCOClaire de Oliveira
- Scott BlommaertSBScott Blommaert
- Reka E. PatakyRPReka E. Pataky
- David TranDTDavid Tran
- Zeb AurangzebZAZeb Aurangzeb
- Cynthia KendellCKCynthia Kendell
- Chris FolkinsCFChris Folkins
- Chandy SomayajiCSChandy Somayaji
- Jeff DowdenJDJeff Dowden
- Winson CheungWCWinson Cheung
- Erin StrumpfESErin Strumpf
Open Access
- 17 March 2022
- journal article
- editorial
- Published by MDPI AG in Current Oncology
- Vol. 29 (3) , 2046-2063
Abstract
Canadian provinces routinely collect patient-level data for administrative purposes. These real-world data (RWD) can be used to generate real-world evidence (RWE) to inform clinical care and healthcare policy. The CanREValue Collaboration is developing a framework for the use of RWE in cancer drug funding decisions. A Data Working Group (WG) was established to identify data assets across Canada for generating RWE of oncology drugs. The mapping exercise was conducted using an iterative scan with informant surveys and teleconference. Data experts from ten provinces convened for a total of three teleconferences and two in-person meetings from March 2018 to September 2019. Following each meeting, surveys were developed and shared with the data experts which focused on identifying databases and data elements, as well as a feasibility assessment of conducting RWE studies using existing data elements and resources. Survey responses were compiled into an interim data report, which was used for public stakeholder consultation. The feedback from the public consultation was used to update the interim data report. We found that databases required to conduct real-world studies are often held by multiple different data custodians. Ninety-seven databases were identified across Canada. Provinces held on average 9 distinct databases (range: 8–11). An Essential RWD Table was compiled that contains data elements that are necessary, at a minimal, to conduct an RWE study. An Expanded RWD Table that contains a more comprehensive list of potentially relevant data elements was also compiled and the availabilities of these data elements were mapped. While most provinces have data on patient demographics (e.g., age, sex) and cancer-related variables (e.g., morphology, topography), the availability and linkability of data on cancer treatment, clinical characteristics (e.g., morphology and topography), and drug costs vary among provinces. Based on current resources, data availability, and access processes, data experts in most provinces noted that more than 12 months would be required to complete an RWE study. The CanREValue Collaboration’s Data WG identified key data holdings, access considerations, as well as gaps in oncology treatment-specific data. This data catalogue can be used to facilitate future oncology-specific RWE analyses across Canada.Keywords
Funding Information
- Canadian Institutes of Health Research (154126)
This publication has 42 references indexed in Scilit:
- Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countriesThe European Journal of Health Economics, 2017
- Real-World Evidence — What Is It and What Can It Tell Us?New England Journal of Medicine, 2016
- Treatment Patterns and Survival in Patients with ALK-Positive Non-small-Cell Lung Cancer: A Canadian Retrospective StudyCurrent Oncology, 2016
- Cancer registries in Europe—going forward is the only optionecancermedicalscience, 2016
- Uses of cancer registries for public health and clinical research in Europe: Results of the European Network of Cancer Registries survey among 161 population-based cancer registries during 2010–2012European Journal of Cancer, 2015
- Use of administrative medical databases in population-based researchJournal of Epidemiology and Community Health, 2013
- A review of Canadian health care and cancer care systemsCancer, 2011
- Potential use of routine databases in health technology assessmentHealth Technology Assessment, 2005
- The promise of e-health--a Canadian perspective.2004
- The development of health technology assessmentHealth Policy, 2003